IP Library Granted Patent US 8,206,685
Granted Patent B2
US 8,206,685 · App. 12/754,197 · Granted Jun 26, 2012

Cupredoxin derived transport agents and methods of use thereof

Assignee: The Board of Trustees of The University of Illinois
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,206,685
App. No.
12/754,197
Granted
Jun 26, 2012
Kind
B2
Abstract

The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.

Claims (9)

1. A method for imaging cancer in a patient, comprising:

administering to said patient a complex comprising a cargo compound that comprises a detectable substance, said cargo compound linked to a peptide that consists of a sequence that is a truncation of a full-length wild-type cupredoxin or a H.8 outer membrane protein, wherein the peptide facilitates entry of the cargo compound into a mammalian cancer cell; and

detecting the location of the cargo compound in said patient.

2. The method of claim 1 , wherein the cargo compound is, an X-ray contrast agent and the location of the cargo compound is detected by X-ray CT.

3. The method of claim 1 , wherein the cargo compound is a magnetic resonance imaging contrast agent and the location of the cargo compound is detected by MRI.

4. The method of claim 1 , wherein the cargo compound is an ultrasound contrast, agent and the location of the cargo compound is detected by ultrasound imaging.

5. A method for diagnosing cancer, comprising:

contacting a cell with a complex comprising a cargo compound that comprises a detectable substance, said cargo compound linked to a peptide that consists of a sequence that is a truncation of a full-length wild-type cupredoxin or a H.8 outer membrane protein, wherein the peptide facilitates entry of the cargo compound into a mammalian cancer cell; and

detecting the location of the cargo compound.

Continuity (5)
Continuation 11244105 · Oct 6, 2005
Provisional Application 60700297 · Jul 19, 2005
Provisional Application 60680500 · May 13, 2005
Provisional Application 60616782 · Oct 7, 2004
Related Publication 20100209355A1 · Aug 19, 2010